[The results of a comparative clinical study of the antiestrogenic preparations toremifene and tamoxifen in locally advanced and disseminated breast cancer].
A randomized clinical trial performed in 50 female patients with advanced breast cancer showed 60 mg/day and 240 mg/day toremifene and 40 mg/day tamoxifen to be nearly equally effective. Partial, with few exceptions, response lasting 5-31 months was observed in 35-50% of cases whereas another 35-50% of patients showed no change. Toxicity was low.
Konstantinova
M M
MM
Gershanovich
M A
MA
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007844:Latvia; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008593:Menopause / Q000187:drug effects; D008875:Middle Aged; D012074:Remission Induction; D013629:Tamoxifen / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D017312:Toremifene; D014586:USSR
D000970:Antineoplastic Agents; D004965:Estrogen Antagonists; D013629:Tamoxifen; D017312:Toremifene
Rezul'taty sravnitel'nogo klinicheskogo izucheniia antiéstrogennykh preparatov toremifena i tamoksifena pri mestno-rasprostranennom i disseminirovannom rake molochnoĭ zhelezy.